nach oben

Zeitschrift für Rheumatologie

Erschienen in:

22.04.2020 | Systemische Sklerodermie | Leitthema

Mesenchymale Stammzelltherapie bei Autoimmunerkrankungen

verfasst von: apl. Prof. Dr. med. habil. Gernot Keyßer

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Mesenchymale Stroma- oder Stammzellen (MSC) besitzen starke immunmodulierende Eigenschaften. Durch ihr großes Potenzial zur Differenzierung in verschiedene Zellformen sind sie zudem in der Lage, die Reparatur von Gewebeschäden in Gang zu setzen. Bei einer Reihe von rheumatischen Erkrankungen haben sich in vitro Einschränkungen der MSC-Funktion darstellen lassen, auch wenn die Bedeutung dieser Phänomene für die Pathogenese jener Krankheiten nicht abschließend geklärt ist. Dennoch könnte v. a. die allogene, möglicherweise auch die autologe MSC-Transplantation (MSCT) ein interessantes Instrument für die Therapie schwerer rheumatologischer Autoimmunerkrankungen darstellen. Erste klinische Studien haben positive Effekte bei systemischem Lupus erythematodes, der systemischen Sklerodermie, dem Sjögren-Syndrom und anderen Erkrankungen des rheumatischen Formenkreises berichtet. Allerdings sind die Fragen nach der langfristigen Wirkung und Sicherheit ebenso unbeantwortet wie die Frage nach der besten Quelle von MSC, der optimalen Kultivierungstechnik und der effektivsten Applikationsart.

Alexander T, Badoglio M, Henes J et al. (2020) Autologe hämatopoetische Stammzelltransplantation bei Autoimmunerkrankungen. Z Rheumatol. https://doi.org/10.1007/s00393-020-00795-2 CrossRefPubMed

Zupan J, Drobnic M, Strazar K (2019) Synovium-derived mesenchymal stem/stromal cells and their promise for cartilage regeneration. Adv Exp Med Biol. https://doi.org/10.1007/5584_2019_381 CrossRef

To K, Zhang B, Romain K et al (2019) Synovium-derived mesenchymal stem cell transplantation in cartilage regeneration: a PRISMA review of in vivo studies. Front Bioeng Biotechnol 7:314. https://doi.org/10.3389/fbioe.2019.00314 CrossRefPubMedPubMedCentral

Xu H, Huang S, Wang J et al (2019) Enhanced cutaneous wound healing by functional injectable thermo-sensitive chitosan-based hydrogel encapsulated human umbilical cord-mesenchymal stem cells. Int J Biol Macromol 137:433–441. https://doi.org/10.1016/j.ijbiomac.2019.06.246 CrossRefPubMed

Esmaeilzade B, Artimani T, Amiri I et al (2019) Dimethyloxalylglycine preconditioning enhances protective effects of bone marrow-derived mesenchymal stem cells in Abeta-induced Alzheimer disease. Physiol Behav 199:265–272. https://doi.org/10.1016/j.physbeh.2018.11.034 CrossRefPubMed

Hamed GM, Morsy WE, Hamid MSA et al (2019) Effect of bone marrow-derived mesenchymal stem cells on ischaemic-reperfused hearts in adult rats with established chronic kidney disease. Int J Stem Cells 12:304–314. https://doi.org/10.15283/ijsc18114 CrossRefPubMedPubMedCentral

Cetinkaya B, Unek G, Kipmen-Korgun D et al (2019) Effects of human placental amnion derived mesenchymal stem cells on proliferation and apoptosis mechanisms in chronic kidney disease in the rat. Int J Stem Cells 12:151–161. https://doi.org/10.15283/ijsc18067 CrossRefPubMed

Qi Y, Ma J, Li S et al (2019) Applicability of adipose-derived mesenchymal stem cells in treatment of patients with type 2 diabetes. Stem Cell Res Ther 10:274. https://doi.org/10.1186/s13287-019-1362-2 CrossRefPubMedPubMedCentral

Ding SSL, Subbiah SK, Khan MSA et al (2019) Empowering mesenchymal stem cells for ocular degenerative disorders. Int J Stem Cells. https://doi.org/10.3390/ijms20071784 CrossRef

10.

Nauta AJ, Fibbe WE (2007) Immunomodulatory properties of mesenchymal stromal cells. Blood 110:3499–3506. https://doi.org/10.1182/blood-2007-02-069716 CrossRefPubMed

11.

Friedenstein AJ, Chailakhyan RK, Latsinik NV et al (1974) Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17:331–340. https://doi.org/10.1097/00007890-197404000-00001 CrossRefPubMed

12.

Friedenstein AJ, Petrakova KV, Kurolesova AI et al (1968) Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6:230–247CrossRefPubMed

13.

Maria AT, Maumus M, Le Quellec A et al (2017) Adipose-derived mesenchymal stem cells in autoimmune disorders: state of the art and perspectives for systemic sclerosis. Clin Rev Allergy Immunol 52:234–259. https://doi.org/10.1007/s12016-016-8552-9 CrossRefPubMed

14.

Montesinos JJ, Flores-Figueroa E, Castillo-Medina S et al (2009) Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression. Cytotherapy 11:163–176. https://doi.org/10.1080/14653240802582075 CrossRefPubMed

15.

da Silva Meirelles L, Chagastelles PC, Nardi NB (2006) Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 119:2204–2213. https://doi.org/10.1242/jcs.02932 CrossRefPubMed

16.

De Ugarte DA, Morizono K, Elbarbary A et al (2003) Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 174:101–109. https://doi.org/10.1159/000071150 CrossRefPubMed

17.

Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317. https://doi.org/10.1080/14653240600855905 CrossRefPubMed

18.

Maria AT, Toupet K, Maumus M et al (2016) Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis. J Autoimmun 70:31–39. https://doi.org/10.1016/j.jaut.2016.03.013 CrossRefPubMed

19.

Phinney DG, Sensebe L (2013) Mesenchymal stromal cells: misconceptions and evolving concepts. Cytotherapy 15:140–145. https://doi.org/10.1016/j.jcyt.2012.11.005 CrossRefPubMed

20.

Luz-Crawford P, Kurte M, Bravo-Alegria J et al (2013) Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther 4:65. https://doi.org/10.1186/scrt216 CrossRefPubMedPubMedCentral

21.

Mougiakakos D, Jitschin R, Johansson CC et al (2011) The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117:4826–4835. https://doi.org/10.1182/blood-2010-12-324038 CrossRefPubMed

22.

Prigione I, Benvenuto F, Bocca P et al (2009) Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells 27:693–702. https://doi.org/10.1634/stemcells.2008-0687 CrossRefPubMed

23.

Corcione A, Benvenuto F, Ferretti E et al (2006) Human mesenchymal stem cells modulate B‑cell functions. Blood 107:367–372. https://doi.org/10.1182/blood-2005-07-2657 CrossRefPubMed

24.

Jiang XX, Zhang Y, Liu B et al (2005) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105:4120–4126. https://doi.org/10.1182/blood-2004-02-0586 CrossRefPubMed

25.

Luz-Crawford P, Djouad F, Toupet K et al (2016) Mesenchymal stem cell-derived Interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. Stem Cells 34:483–492. https://doi.org/10.1002/stem.2254 CrossRefPubMed

26.

Schmitt M, Muller LP, Keysser G et al (2013) Mesenchymal stroma cells (MSCs) for the treatment of rheumatic disease. Dtsch Med Wochenschr 138:1852–1855. https://doi.org/10.1055/s-0033-1343346 CrossRefPubMed

27.

Luz-Crawford P, Noel D, Fernandez X et al (2012) Mesenchymal stem cells repress Th17 molecular program through the PD‑1 pathway. Plos One 7:e45272. https://doi.org/10.1371/journal.pone.0045272 CrossRefPubMedPubMedCentral

28.

Djouad F, Plence P, Bony C et al (2003) Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102:3837–3844. https://doi.org/10.1182/blood-2003-04-1193 CrossRefPubMed

29.

Luz-Crawford P, Torres MJ, Noel D et al (2016) The immunosuppressive signature of menstrual blood mesenchymal stem cells entails opposite effects on experimental arthritis and graft versus host diseases. Stem Cells 34:456–469. https://doi.org/10.1002/stem.2244 CrossRefPubMed

30.

Noel D, Caton D, Roche S et al (2008) Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res 314:1575–1584. https://doi.org/10.1016/j.yexcr.2007.12.022 CrossRefPubMed

31.

Wegmeyer H, Broske AM, Leddin M et al (2013) Mesenchymal stromal cell characteristics vary depending on their origin. Stem Cells Dev 22:2606–2618. https://doi.org/10.1089/scd.2013.0016 CrossRefPubMedPubMedCentral

32.

Bochev I, Elmadjian G, Kyurkchiev D et al (2008) Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B‑cell immunoglobulin production in vitro. Cell Biol Int 32:384–393. https://doi.org/10.1016/j.cellbi.2007.12.007 CrossRefPubMed

33.

Rivera-Izquierdo M, Cabeza L, Lainez-Ramos-Bossini A et al (2019) An updated review of adipose derived-mesenchymal stem cells and their applications in musculoskeletal disorders. Expert Opin Biol Ther 19:233–248. https://doi.org/10.1080/14712598.2019.1563069 CrossRefPubMed

34.

Nie Y, Lau C, Lie A et al (2010) Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 19:850–859. https://doi.org/10.1177/0961203309361482 CrossRefPubMed

35.

Kastrinaki MC, Sidiropoulos P, Roche S et al (2008) Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis 67:741–749. https://doi.org/10.1136/ard.2007.076174 CrossRefPubMed

36.

Cipriani P, Di Benedetto P, Ruscitti P et al (2014) Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features. Arthritis Res Ther 16:442. https://doi.org/10.1186/s13075-014-0442-z CrossRefPubMedPubMedCentral

37.

Sun Y, Deng W, Geng L et al (2015) Mesenchymal stem cells from patients with rheumatoid arthritis display impaired function in inhibiting Th17 cells. J Immunol Res. https://doi.org/10.1155/2015/284215 CrossRefPubMedPubMedCentral

38.

Augello A, Tasso R, Negrini SM et al (2007) Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 56:1175–1186. https://doi.org/10.1002/art.22511 CrossRefPubMed

39.

Abdelmawgoud H, Saleh A (2018) Anti-inflammatory and antioxidant effects of mesenchymal and hematopoietic stem cells in a rheumatoid arthritis rat model. Adv Clin Exp Med 27:873–880. https://doi.org/10.17219/acem/73720 CrossRefPubMed

40.

Ma D, Xu K, Zhang G et al (2019) Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in rheumatoid arthritis. Int J Immunopharmacol 74:105687. https://doi.org/10.1016/j.intimp.2019.105687 CrossRef

41.

Bouffi C, Bony C, Courties G et al (2010) IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. Plos One 5:e14247. https://doi.org/10.1371/journal.pone.0014247 CrossRefPubMedPubMedCentral

42.

Toupet K, Maumus M, Luz-Crawford P et al (2015) Survival and biodistribution of xenogenic adipose mesenchymal stem cells is not affected by the degree of inflammation in arthritis. PLoS ONE 10:e114962. https://doi.org/10.1371/journal.pone.0114962 CrossRefPubMedPubMedCentral

43.

Kuo TK, Hung SP, Chuang CH et al (2008) Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 134:2111–2121, 2121 e2111–2113. https://doi.org/10.1053/j.gastro.2008.03.015 CrossRefPubMed

44.

Toupet K, Maumus M, Peyrafitte JA et al (2013) Long-term detection of human adipose-derived mesenchymal stem cells after intraarticular injection in SCID mice. Arthritis Rheum 65:1786–1794. https://doi.org/10.1002/art.37960 CrossRefPubMed

45.

Spaggiari GM, Capobianco A, Becchetti S et al (2006) Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107:1484–1490. https://doi.org/10.1182/blood-2005-07-2775 CrossRefPubMed

46.

Nauta AJ, Westerhuis G, Kruisselbrink AB et al (2006) Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108:2114–2120. https://doi.org/10.1182/blood-2005-11-011650 CrossRefPubMedPubMedCentral

47.

Poggi A, Zocchi MR (2019) Immunomodulatory properties of mesenchymal stromal cells: still unresolved “yin and yang”. Curr Stem Cell Res Ther 14:344–350. https://doi.org/10.2174/1574888X14666181205115452 CrossRefPubMed

48.

Neri S (2019) Genetic stability of mesenchymal stromal cells for regenerative medicine applications: a fundamental Biosafety aspect. IJMS. https://doi.org/10.3390/ijms20102406 CrossRefPubMedPubMedCentral

49.

Wang L, Cong X, Liu G et al (2013) Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cells Dev 22:3192–3202. https://doi.org/10.1089/scd.2013.0023 CrossRefPubMed

50.

Park EH, Lim HS, Lee S et al (2018) Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: a phase Ia clinical trial. Stem Cells Transl Med 7:636–642. https://doi.org/10.1002/sctm.18-0031 CrossRefPubMedPubMedCentral

51.

Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J et al (2019) Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran. Biomed Pharmacother 109:1834–1840. https://doi.org/10.1016/j.biopha.2018.11.056 CrossRefPubMed

52.

Li A, Tao Y, Kong D et al (2017) Infusion of umbilical cord mesenchymal stem cells alleviates symptoms of ankylosing spondylitis. Exp Ther Med 14:1538–1546. https://doi.org/10.3892/etm.2017.4687 CrossRefPubMedPubMedCentral

53.

Keyszer G, Christopeit M, Fick S et al (2011) Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. Arthritis Rheum 63:2540–2542. https://doi.org/10.1002/art.30431 CrossRefPubMed

54.

Zhang H, Liang J, Tang X et al (2017) Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis. Arthritis Res Ther 19:165. https://doi.org/10.1186/s13075-017-1373-2 CrossRefPubMedPubMedCentral

55.

Del Papa N, Di Luca G, Sambataro D et al (2015) Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis. Cell Transplant 24:2297–2305. https://doi.org/10.3727/096368914X685636 CrossRefPubMed

56.

Granel B, Daumas A, Jouve E et al (2015) Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis 74:2175–2182. https://doi.org/10.1136/annrheumdis-2014-205681 CrossRefPubMed

57.

Sun L, Wang D, Liang J et al (2010) Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 62:2467–2475. https://doi.org/10.1002/art.27548 CrossRefPubMed

58.

Liang J, Zhang H, Hua B et al (2010) Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 69:1423–1429. https://doi.org/10.1136/ard.2009.123463 CrossRefPubMed

59.

Li X, Wang D, Liang J et al (2013) Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus. Bone Marrow Transplant 48:544–550. https://doi.org/10.1038/bmt.2012.184 CrossRefPubMed

60.

Gu F, Wang D, Zhang H et al (2014) Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clin Rheumatol 33:1611–1619. https://doi.org/10.1007/s10067-014-2754-4 CrossRefPubMed

61.

Wang D, Li J, Zhang Y et al (2014) Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther 16:R79. https://doi.org/10.1186/ar4520 CrossRefPubMedPubMedCentral

62.

Xu J, Wang D, Liu D et al (2012) Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood 120:3142–3151. https://doi.org/10.1182/blood-2011-11-391144 CrossRefPubMedPubMedCentral

63.

Pedrosa M, Gomes J, Laranjeira P et al (2019) Immunomodulatory effect of human bone marrow-derived mesenchymal stromal/stem cells on peripheral blood T cells from rheumatoid arthritis patients. J Tissue Eng Regen Med. https://doi.org/10.1002/term.2958 CrossRefPubMed

64.

Gonzalez-Rey E, Gonzalez MA, Varela N et al (2010) Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis 69:241–248. https://doi.org/10.1136/ard.2008.101881 CrossRefPubMed

65.

Huang ZF, Lu SH, Zhu J et al (2013) Inhibitory effects of human umbilical cord-derived mesenchymal stem cells on proliferation of peripheral blood mononuclear cells from spondyloarthritis patients. Zhonghua Yi Xue Za Zhi 93:1499–1502PubMed

66.

Huang ZF, Zhu J, Lu SH et al (2013) Inhibitory effect of human umbilical cord-derived mesenchymal stem cells on interleukin-17 production in peripheral blood T cells from spondyloarthritis patients. Zhongguo Shi Yan Xue Ye Xue Za Zhi 21:455–459. https://doi.org/10.7534/j.issn.1009-2137.2013.02.041 CrossRefPubMed

67.

Wang P, Li Y, Huang L et al (2014) Effects and safety of allogenic mesenchymal stem cell intravenous infusion in active ankylosing spondylitis patients who failed NSAIDs: a 20-week clinical trial. Cell Transplant 23:1293–1303. https://doi.org/10.3727/096368913X667727 CrossRefPubMed

68.

Abdolmohammadi K, Pakdel FD, Aghaei H et al (2019) Ankylosing spondylitis and mesenchymal stromal/stem cell therapy: a new therapeutic approach. Biomed Pharmacother 109:1196–1205. https://doi.org/10.1016/j.biopha.2018.10.137 CrossRefPubMed

69.

Berthelot JM, Le Goff B, Maugars Y (2019) Bone marrow mesenchymal stem cells in rheumatoid arthritis, spondyloarthritis, and ankylosing spondylitis: problems rather than solutions? Arthritis Res Ther 21:239. https://doi.org/10.1186/s13075-019-2014-8 CrossRefPubMedPubMedCentral

70.

Layh-Schmitt G, Lu S, Navid F et al (2017) Generation and differentiation of induced pluripotent stem cells reveal ankylosing spondylitis risk gene expression in bone progenitors. Clin Rheumatol 36:143–154. https://doi.org/10.1007/s10067-016-3469-5 CrossRefPubMed

71.

Del Papa N, Quirici N, Soligo D et al (2006) Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 54:2605–2615. https://doi.org/10.1002/art.22035 CrossRefPubMed

72.

Rozier P, Maria A, Goulabchand R et al (2018) Mesenchymal stem cells in systemic sclerosis: allogenic or autologous approaches for therapeutic use? Front Immunol 9:2938. https://doi.org/10.3389/fimmu.2018.02938 CrossRefPubMedPubMedCentral

73.

Di Benedetto P, Panzera N, Cipriani P et al (2019) Mesenchymal stem cells of systemic sclerosis patients, derived from different sources, show a profibrotic microRNA profiling. Sci Rep 9:7144. https://doi.org/10.1038/s41598-019-43638-0 CrossRefPubMedPubMedCentral

74.

Cipriani P, Guiducci S, Miniati I et al (2007) Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 56:1994–2004. https://doi.org/10.1002/art.22698 CrossRefPubMed

75.

Fonteneau G, Bony C, Goulabchand R et al (2017) Serum-mediated oxidative stress from systemic sclerosis patients affects mesenchymal stem cell function. Front Immunol 8:988. https://doi.org/10.3389/fimmu.2017.00988 CrossRefPubMedPubMedCentral

76.

Larghero J, Farge D, Braccini A et al (2008) Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis 67:443–449. https://doi.org/10.1136/ard.2007.071233 CrossRefPubMed

77.

Capelli C, Zaccara E, Cipriani P et al (2017) Phenotypical and functional characteristics of in vitro-expanded adipose-derived mesenchymal stromal cells from patients with systematic sclerosis. Cell Transplant 26:841–854. https://doi.org/10.3727/096368917X694822 CrossRefPubMedPubMedCentral

78.

Griffin M, Ryan CM, Pathan O et al (2017) Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine. Stem Cell Res Ther 8:23. https://doi.org/10.1186/s13287-016-0444-7 CrossRefPubMedPubMedCentral

79.

Gao L, Zhang Y, Hu B et al (2016) Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation. J Clin Oncol 34:2843–2850. https://doi.org/10.1200/JCO.2015.65.3642 CrossRefPubMed

80.

Ferreli C, Gasparini G, Parodi A et al (2017) Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review. Clin Rev Allergy Immunol 53:306–336. https://doi.org/10.1007/s12016-017-8625-4 CrossRefPubMed

81.

Wehbe T, Abi Saab M, Abi Chahine N et al (2016) Mesenchymal stem cell therapy for refractory scleroderma: a report of 2 cases. Stem Cell Investig 3:48. https://doi.org/10.21037/sci.2016.09.03 CrossRefPubMedPubMedCentral

82.

Magalon J, Velier M, Simoncini S et al (2019) Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis. Ann Rheum Dis 78:391–398. https://doi.org/10.1136/annrheumdis-2018-214218 CrossRefPubMed

83.

Guillaume-Jugnot P, Daumas A, Magalon J et al (2016) Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up. Baillieres Clin Rheumatol 55:301–306. https://doi.org/10.1093/rheumatology/kev323 CrossRef

84.

Li X, Liu L, Meng D et al (2012) Enhanced apoptosis and senescence of bone-marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Stem Cells Dev 21:2387–2394. https://doi.org/10.1089/scd.2011.0447 CrossRefPubMed

85.

Sun LY, Zhang HY, Feng XB et al (2007) Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 16:121–128. https://doi.org/10.1177/0961203306075793 CrossRefPubMed

86.

Carrion F, Nova E, Ruiz C et al (2010) Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 19:317–322. https://doi.org/10.1177/0961203309348983 CrossRefPubMed

87.

Zhou K, Zhang H, Jin O et al (2008) Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 5:417–424. https://doi.org/10.1038/cmi.2008.52 CrossRefPubMedPubMedCentral

88.

Sun L, Akiyama K, Zhang H et al (2009) Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27:1421–1432. https://doi.org/10.1002/stem.68 CrossRefPubMedPubMedCentral

89.

Liang J, Gu F, Wang H et al (2010) Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE. Nat Rev Rheumatol 6:486–489. https://doi.org/10.1038/nrrheum.2010.80 CrossRefPubMed

90.

Shi D, Wang D, Li X et al (2012) Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus. Clin Rheumatol 31:841–846. https://doi.org/10.1007/s10067-012-1943-2 CrossRefPubMed

91.

Wang D, Niu L, Feng X et al (2017) Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. Clin Exp Med 17:333–340. https://doi.org/10.1007/s10238-016-0427-0 CrossRefPubMed

92.

Wang SQ, Wang YX, Hua H (2017) Characteristics of labial gland mesenchymal stem cells of healthy individuals and patients with Sjogren’s syndrome: a preliminary study. Stem Cells Dev 26:1171–1185. https://doi.org/10.1089/scd.2017.0045 CrossRefPubMed

93.

Liu Y, Li C, Wang S et al (2019) Human umbilical cord mesenchymal stem cells confer potent immunosuppressive effects in Sjogren’s syndrome by inducing regulatory T cells. Mod Rheumatol 20:1–25. https://doi.org/10.1080/14397595.2019.1707996 CrossRef

94.

Gregorini M, Maccario R, Avanzini MA et al (2013) Antineutrophil cytoplasmic antibody-associated renal vasculitis treated with autologous mesenchymal stromal cells: evaluation of the contribution of immune-mediated mechanisms. Mayo Clin Proc 88:1174–1179. https://doi.org/10.1016/j.mayocp.2013.06.021 CrossRefPubMed

95.

Davatchi F, Nikbin B, Shams H et al (2013) Mesenchymal stem cell therapy unable to rescue the vision from advanced Behcet’s disease retinal vasculitis: report of three patients. Int J Rheum Dis 16:139–147. https://doi.org/10.1111/1756-185X.12068 CrossRefPubMed

96.

Naji A, Eitoku M, Favier B et al (2019) Biological functions of mesenchymal stem cells and clinical implications. Cell Mol Life Sci 76:3323–3348. https://doi.org/10.1007/s00018-019-03125-1 CrossRefPubMed

Titel: Mesenchymale Stammzelltherapie bei Autoimmunerkrankungen
verfasst von: apl. Prof. Dr. med. habil. Gernot Keyßer
Publikationsdatum: 22.04.2020
Verlag: Springer Medizin
Schlagwörter: Systemische Sklerodermie
Systemischer Lupus erythematodes
Rheumatoide Arthritis
Sklerodermie
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe 5/2020
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-020-00790-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Mesenchymale Stammzelltherapie bei Autoimmunerkrankungen

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Immunoglobulin G4-related thoracic aortitis

Autologe hämatopoetische Stammzelltransplantation bei Autoimmunerkrankungen

Association between IL-17 gene polymorphisms and circulating IL-17 levels in osteoarthritis: a meta-analysis

Autologe hämatopoetische Stammzelltransplantation bei systemischer Sklerose

Zelltherapien

Mitteilungen der DGRh

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin